What is InSphero?
InSphero operates at the intersection of biotechnology and advanced materials science, specializing in the development of sophisticated 3D cell culture and organ-on-a-chip systems. These cutting-edge platforms are designed to replicate human physiology with remarkable accuracy, producing microtissues that mimic native organs such as the liver, tumors, and pancreas. By offering these highly predictive models, InSphero empowers pharmaceutical and biotechnology companies to enhance their drug discovery pipelines and improve the safety testing of new compounds. The company's technology aims to reduce the reliance on traditional animal models and accelerate the transition of promising drug candidates from laboratory research to clinical trials, thereby optimizing the development process and potentially lowering associated costs.
How much funding has InSphero raised?
InSphero has raised a total of $36.1M across 5 funding rounds:
Series A
$1.9M
Series B
$2.2M
Series C
$21.1M
Unspecified
$850K
Unspecified
$10M
Series A (2010): $1.9M with participation from Redalpine Venture Partners
Series B (2013): $2.2M, investors not publicly disclosed
Series C (2015): $21.1M, investors not publicly disclosed
Unspecified (2015): $850K, investors not publicly disclosed
Unspecified (2018): $10M backed by Venturelab
Key Investors in InSphero
Venturelab
Venturelab is a Swiss organization dedicated to supporting startups through entrepreneurship and innovation programs, with a focus on fostering investment and business development for early-stage companies.
Redalpine Venture Partners
Redalpine is a thesis-driven venture capital firm established in 2006, specializing in software and science, aiming to empower disruptive innovations and support technical companies with strategic guidance.
What's next for InSphero?
With the recent major strategic investment, InSphero is poised for significant expansion and further technological advancement. The capital infusion is anticipated to fuel the scaling of its manufacturing capabilities, enhance its research and development efforts in novel microtissue applications, and broaden its market reach globally. This strategic backing suggests a focus on solidifying its position as a key enabler of precision medicine and personalized therapeutics. InSphero's continued growth trajectory, marked by this substantial financing, indicates a strong market demand for its innovative 3D cell culture solutions and a promising outlook for its contribution to the future of pharmaceutical R&D.
See full InSphero company page
